ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that the Pittsburgh Technology Council has named ZOLL's Pittsburgh, Pa. facility, which manufactures and sells the LifeVest® Wearable Defibrillator, as a 2010 Tech 50 Awards finalist for the second consecutive year.

The Pittsburgh Technology Council's Tech 50 Awards recognize southwestern Pennsylvania technology leaders whose pioneering innovations have been instrumental in developing and driving Pittsburgh's economy.

This selection of ZOLL Pittsburgh was based largely on the company's dramatic revenue growth over the past three years. In addition, ZOLL was selected based on its accomplishments in the areas of technological innovation, job creation, and employee retention.

?It is a great honor to have ZOLL recognized for the second year in a row as one of the Pittsburgh Technology Council's Tech 50 Awards finalists,? said Richard A. Packer, Chief Executive Officer of ZOLL. ?We are especially pleased with the performance of our LifeVest business, with sales growth above 50 percent for each of the last four years. The LifeVest is emerging as a standard of care to protect patients during temporary or changing risk of sudden cardiac arrest, and until a permanent risk is established.?

?There was a 38 percent increase in nominations this year and the judges found selecting only 50 finalists to be extremely challenging,? explained Audrey Russo, President and Chief Executive Officer of the Pittsburgh Technology Council. ?As with last year, our judges were very impressed by ZOLL's innovative work in protecting patients from sudden cardiac arrest with the LifeVest, but also what these accomplishments mean for the Pittsburgh region as a whole.?

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from sudden cardiac arrest. The LifeVest continuously monitors the patient's heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk. To date, the LifeVest has been prescribed to over 25,000 patients. For more information, go to www.zoll.com or 1.800.543.3267.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and/or manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are ?forward-looking? statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled ?Risk Factors? in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2010. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and LifeVest are registered trademarks of ZOLL Medical Corporation.

INVESTOR CONTACT:
ZOLL Medical Corporation
A. Ernest Whiton, +1-978-421-9655
Chief Financial Officer
or
MEDIA CONTACT:
ZOLL Medical Corporation
Diane Egan, +1-978-421-9637
degan@zoll.com